CVRx to Announce Financial Results and Insights
CVRx, Inc. (NASDAQ: CVRX), a pioneering medical device company situated in the vibrant realm of healthcare innovation, is gearing up to unveil its fourth quarter financial and operational performance. This much-anticipated announcement is slated for release following the market close on February 4, 2025. Investors and stakeholders are encouraged to join the corresponding conference call to glean insights into the company's progress and future directions.
Conference Call Information
On the same day as the financial results announcement, CVRx will host a live conference call at 4:30 PM Eastern Time. This event will serve as a platform for the company to discuss its performance and engage with the investment community. Participants can access the conference call via telephone; U.S. callers can dial 1-877-704-4453, while international participants should call 1-201-389-0920 approximately ten minutes before the meeting begins.
Webcast Availability
The investor conference call will also be streamed live through a webcast, available on the investor relations section of the CVRx website. This provides a convenient option for those who prefer to listen online or view accompanying materials in real time.
Innovative Solutions in Cardiac Care
CVRx specializes in developing and commercializing cutting-edge neuromodulation therapies for patients grappling with cardiovascular issues. Their flagship product, the Barostim™ device, stands out as the first FDA-approved technology in its category aimed at alleviating symptoms in patients with heart failure. By delivering gentle electrical pulses to baroreceptors within the carotid artery's walls, Barostim works to recalibrate the body’s autonomic nervous system, offering significant relief.
Clinical Impact of Barostim
This innovative device has positioned itself as a game-changer for heart failure patients. Notably, Barostim is designated as an FDA Breakthrough Device, reflecting its potential to meet unmet medical needs effectively. Its availability is expanding, having already received CE Mark approval for use in heart failure and resistant hypertension across the European Economic Area, further underscoring its significance in modern cardiac care.
Connect With CVRx
As CVRx continues to forge ahead, staying updated with the latest from the company is crucial for interested parties. The commitment to innovation in medical devices is at the heart of CVRx's mission, ensuring they remain at the forefront of addressing pressing health challenges. Investors looking for further information or who have inquiries are encouraged to connect directly through the company's investor relations team.
Investor and Media Contacts
For investor-related inquiries, Mark Klausner and Mike Vallie from ICR Westwicke can be reached at 443-213-0501. Additionally, media inquiries can be directed to Emily Meyers at CVRx, providing another channel for communication and information dissemination.
Frequently Asked Questions
What is the significance of the upcoming conference call?
The conference call will allow CVRx to discuss its fourth quarter financial results and future plans, giving investors insights into the company's direction and performance.
What is Barostim and its importance?
Barostim is an innovative neuromodulation device approved by the FDA for heart failure treatment, designed to help restore balance in the autonomic nervous system.
How can I participate in the conference call?
To participate, dial 1-877-704-4453 for U.S. callers or 1-201-389-0920 for international callers, around ten minutes before the scheduled start time.
Where can I find more information about CVRx?
More information about CVRx and its products, including Barostim, can be found on their official website.
Who can I contact for investor inquiries?
For investor inquiries, you can reach out to Mark Klausner or Mike Vallie at ICR Westwicke via phone at 443-213-0501.
